News

iECURE, a gene editing company focused on the development of mutation-agnostic in vivo gene insertion, or knock-in, editing therapies for the treatment of liver disorders with…
Read More...

Ribon Therapeutics, a clinical stage biotechnology company developing therapeutics targeting stress support pathways, today announced that it entered into an agreement on the…
Read More...

Ferring Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved REBYOTA (fecal microbiota, live-jslm), a novel first-in-class microbiota-based live biotherapeutic…
Read More...

argenx SE announced an agreement to acquire a U.S. Food and Drug Administration (FDA) Priority Review Voucher (PRV) for $102 million. A PRV entitles the holder to FDA priority review of…
Read More...

Kintara Therapeutics, Inc. announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Kintara's REM-001 Therapy for the treatment of…
Read More...

Aldeyra Therapeutics, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new…
Read More...

Clinigen Limited has agreed to acquire Drug Safety Navigator Inc. (‘DSN’), a specialist pharmacovigilance service provider based in the US. This acquisition enables Clinigen to add…
Read More...

Envisagenics, an Artificial Intelligence ("AI")-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with …
Read More...

Neogene Therapeutics, Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies…
Read More...

Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be…
Read More...

Gilead Sciences, Inc. announced that the European Commission (EC) has authorized a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir…
Read More...

ANI Pharmaceuticals, Inc. announced that the Company received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Fluoxetine Oral…
Read More...

C4X Discovery Holdings plc has signed an exclusive worldwide licensing agreement with AstraZeneca worth up to $402 million, for its NRF2 Activator programme.  AstraZeneca will develop…
Read More...

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement for GARDP to access over 50,000 compounds…
Read More...

AbbVie announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) as the first specific…
Read More...

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their…
Read More...

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate…
Read More...